Bharat Biotech To Double Covaxin Production From 5 Million To 12 Million Doses Per Month By July

Bharat Biotech To Double Covaxin Production From 5 Million To 12 Million Doses Per Month By JulyBharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)

In a boost for India's nationwide COVID-19 vaccination drive, Hyderabad based Bharat Biotech which manufactures Covaxin is set to more than double the monthly production capacity by July from present five million doses to 12 million doses, reports Economic Times.

Having recently secured the necessary approvals from the authorities, the company is soon set to begin the bulk manufacturing of Covaxin at its new facility in Karnataka's capital city of Bengaluru. Dr Krishna Ella led company is also said to be engaging with other companies to further boost the production of Covaxin.

Meanwhile, Adar Poonawalla led Serum Institute of India (SII) is also expected to boost the production of Covishield to 110 million doses per month from June. This would come as a big boost as the present capacity for SII stands at 60-70 million doses per month.

Other than this, it is expected that India will soon also approve the use of the Russian Sputnik V vaccine which will further boost the availability of vaccine supplies in the nation. It is expected that the initial doses of the vaccine will be imported from Russia following which domestic production would begin.